Evidence map›Paper›PMID 40327264›Full record

ArticleAMB Express2025

Engineering Pseudomonas aeruginosa for (R)-3-hydroxydecanoic acid production.

Shuai Wang, Haiying Yu, Kun Zhu

Abstract read
In one paragraph

Article in AMB Express, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Shuai WangCAS Key Laboratory of Microbial Physiological and Metabolic Engineering, Institute of Microbiology, Chinese Academy of Sciences, Beijing, 100101, China.
Haiying YuCAS Key Laboratory of Microbial Physiological and Metabolic Engineering, Institute of Microbiology, Chinese Academy of Sciences, Beijing, 100101, China. yuhy@im.ac.cn.ORCID http://orcid.org/0009-0001-4889-7537
Kun ZhuCAS Key Laboratory of Microbial Physiological and Metabolic Engineering, Institute of Microbiology, Chinese Academy of Sciences, Beijing, 100101, China.

Funding

the National Key R&D Program of China 2021YFC2301000
6 · The paper itself

Abstract

(R)-3-hydroxyalkanoic acids (R-3HAs) play a crucial role as essential chemicals serving as precursors or intermediates in the synthesis of a wide range of valuable compounds, such as pharmaceuticals, antibiotics, and food additives. Despite their significance, achieving industrial-scale production of R-3HAs, particularly medium-chain-length (mcl) R-3HAs, has been challenging due to the absence of suitable strains with efficient biosynthesis pathways. This study focuses on achieving the production of mcl R-3HA monomers by leveraging the "substrate pool" of R-3-(R-3-hydroxyalkanoyloxy) alkanoic acids (HAAs) which is synthesized by HAAs synthase RhlA. The process involved truncating the rhamnolipids synthesis pathway in Pseudomonas aeruginosa PAO1 by knocking out downstream genes rhlB and rhlC, leading to the accumulation and collection of intermediate HAAs from the culture supernatant. To enhance the production of HAAs further, a series of key genes in the β-oxidation pathway were knocked out, resulting in a titer of approximately 18 g/L. Subsequently, hydrolysis of HAAs was conducted under alkaline conditions, where the dimers could be rapidly and efficiently converted into monomers. The hydrolysis process was completed in 2.5 h at 80 °C using a 0.5 M NaOH solution. The primary hydrolysis product identified through GC-MS analysis was (R)-3-hydroxydecanoic acid (R-3HD) with a purity of 95%.

Indexed as

(R)-3-hydroxyalkanoic acid(R)-3-hydroxydecanoic acidR-3-(R-3-hydroxyalkanoyloxy)alkanoic acidRhamnolipids

Identifiers

PMID40327264
PMCPMC12055736

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.